Salvage Cryoablation Safe, Effective for Recurrent Prostate Cancer After Radiotherapy

Share this content:

Salvage targeted cryoablation of the prostate (TCAP) is safe and effective for treating localized prostate cancer recurrence following radiotherapy, according to researchers in the United Kingdom.

 

Investigators at the Royal Surrey County Hospital and St. Luke's Cancer Centre in Guildford, Surrey, studied 100 patients who underwent salvage TCAP for biopsy-confirmed recurrent prostate cancer after radiation failure. They were divided into three groups: high-risk (68 men), intermediate-risk (20), and low-risk (12).

 

The researchers observed no operative or cancer-related deaths during a mean follow-up of 33.5 months. The five-year actuarial biochemical recurrence-free survival for the high-, intermediate-, and low-risk groups was 11%, 45%, and 73%, respectively.

 

With respect to complications, 86% of patients experienced erectile dysfunction, 16% had lower urinary tract symptoms, and 13% had incontinence.

 

Findings appear in BJU International (2007;100:760-764).

You must be a registered member of Renal and Urology News to post a comment.